[Skip to Navigation]
Sign In
Other Articles
December 3, 1960

Agranulocytosis Due to Chlordiazepoxide Hydrochloride

Author Affiliations

Columbus, Ohio; USAF

From the departments of psychiatry and medicine, Ohio State University College of Medicine.

JAMA. 1960;174(14):1863-1865. doi:10.1001/jama.1960.63030140011024b

Only recently was the phase of preliminary testing of chlordiazepoxide hydrochloride completed. The first series of papers dealing with the experiences gathered during experimental trials were reported in the "Symposium on Newer Antidepressant Drugs and Other Psychotherapeutic Drugs," held under the auspices of the University of Texas Medical Branch, Nov. 13-14, in Galveston, Texas. The proceedings of this symposium were published in March, 1960, and are the subject of a "Preliminary Communication" in this journal.1 At about the same time, the drug appeared on the market under the brand name of Librium. Chemically this substance is 7-chloro-2 methylamino-5-phenyl-3H-1,4-benzodiazepine-4-oxide hydrochloride2 (see figure). Apparently, this drug is structurally not related to any of the other tranquilizers. It is specifically recommended for its anxiety-relieving action, and for the lack of those side effects and complications encountered with the phenothiazines. The most notoriously dangerous among these toxic manifestations is agranulocytosis.3


Add or change institution